Engagement in Care, Awareness, and Interest in Long-Acting Injectable Anti-Retroviral Therapy
- PMID: 38954172
- PMCID: PMC11427500
- DOI: 10.1007/s10461-024-04423-x
Engagement in Care, Awareness, and Interest in Long-Acting Injectable Anti-Retroviral Therapy
Abstract
Long Acting Injectable (LAI) therapy to treat HIV is an alternative to daily oral medications. The success of early roll-out of LAI to eligible patients requires a better understanding of patients' awareness and interest in this novel therapy. We administered an electronic survey to patients attending an urban HIV clinic in the US South. Eligible participants were 18 + years old with a most recent HIV-1 viral load < 200 copies/ml, without any evidence of genotypic resistance to LAI components or chronic hepatitis B. Survey recipients were asked about current treatment, engagement in care, and knowledge of LAI. Between January-April 2023, 480 patients were screened; 319 were eligible, and 155 (49%) completed the survey. The majority (119, 77%) were aware of, and 87 (56%) were interested in LAI. In regression analysis, only age was associated with interest in LAI (OR 0.95, 95% CI 0.92,0.99). Among proposed benefits of injectables, ease of travel without pills, lack of daily pill-taking, and fewer medication interactions were most appealing. Among proposed concerns with injectables, higher cost and insurance coverage of the new medicine were most worrisome. A large majority of people with HIV (PWH) are aware of the newest treatment available, and just over half of our sample expressed interest in LAI. Older age was associated with lower interest in LAI. LAI is appealing for its convenience, privacy, and avoidance of drug interactions, while the increased costs associated with LAI need to be addressed.
Keywords: Anti-retroviral therapy; HIV; Long-acting injectables; Treatment preferences.
© 2024. The Author(s).
Conflict of interest statement
JAS, MA, FH, CC, KL, JS have no disclosures to report. MSM receives institutional funding from Gilead Sciences. CM is supported by a grant from the NHLBI, an institute of the NIH (K01HL159052).
Figures



Similar articles
-
"I Feel Like I Don't Even Have HIV Anymore"-Facilitators, Barriers, and Experience regarding Use of Long-Acting Injectable Antiretroviral Therapy Among Persons with HIV in North Carolina.AIDS Patient Care STDS. 2024 Jul;38(7):324-329. doi: 10.1089/apc.2024.0076. Epub 2024 Jun 11. AIDS Patient Care STDS. 2024. PMID: 38860413 Free PMC article.
-
Receipt of long-acting injectable antiretroviral therapy among people with HIV in Southern US states: an assessment using electronic health records and claims data.AIDS Res Ther. 2025 Feb 1;22(1):9. doi: 10.1186/s12981-024-00690-9. AIDS Res Ther. 2025. PMID: 39893464 Free PMC article.
-
Preferences for on-demand/intermittent/event-driven and long-acting injectable (LAI) HIV pre-exposure prophylaxis (PrEP) among HIV-negative Black gay, bisexual, and other sexual minority men in the United States: A qualitative study.PLoS One. 2025 Jun 30;20(6):e0323212. doi: 10.1371/journal.pone.0323212. eCollection 2025. PLoS One. 2025. PMID: 40587467 Free PMC article.
-
Clinical Utility of Long-Acting Injectable Risperidone in Schizophrenia and Bipolar I Disorder: A Review of Clinical Studies.Psychol Res Behav Manag. 2025 Jun 17;18:1455-1469. doi: 10.2147/PRBM.S474513. eCollection 2025. Psychol Res Behav Manag. 2025. PMID: 40548174 Free PMC article. Review.
-
Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.Cochrane Database Syst Rev. 2013 Jun 5;2013(6):CD008270. doi: 10.1002/14651858.CD008270.pub2. Cochrane Database Syst Rev. 2013. PMID: 23740608 Free PMC article.
References
-
- Overton ET, Richmond G, Rizzardini G, et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2 M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. Lancet Dec. 2021;19(10267):1994–2005. - PubMed
-
- Jaeger H, Overton ET, Richmond G, et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2 M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. Lancet HIV Nov. 2021;8(11):e679–89. - PubMed
-
- CAB + RPV Prescribing Info. In. Healthcare V, editor: Food and Drug Administration; 2022.
-
- Biello KB, Hosek S, Drucker MT, et al. Preferences for Injectable PrEP among Young U.S. Cisgender men and Transgender women and men who have sex with men. Arch Sex Behav Oct. 2018;47(7):2101–7. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous